The disclosure provides compounds and methods for treating cancer by inhibiting the formation of cancer cells resistant to paclitaxel by preventing the formation of GBP1:PIM1 protein interaction during a chemotherapeutic treatment. These compounds and methods are able to treat cancer individually or in conjunction with paclitaxel.

The disclosure provides compounds and methods for treating cancer by inhibiting the formation of cancer cells resistant to paclitaxel by preventing the formation of GBP1:PIM1 protein interaction during a chemotherapeutic treatment. These compounds and methods are able to treat cancer individually or in conjunction with paclitaxel.

A heterocyclic compound and an organic light-emitting device including the same, the compound being represented by Formula 1:

A.sub.1-(A.sub.2).sub.a21,  <Formula 1> wherein, in Formula 1, A.sub.1 is a group represented by Formula 2, A.sub.2 is a group represented by Formula 3, and a21 is an integer of 1 to 11, wherein, when a21 is 2 to 11, two or more of A.sub.2 are identical to or different from each other:

##STR00001##

A heterocyclic compound and an organic light-emitting device including the same, the compound being represented by Formula 1:

A.sub.1-(A.sub.2).sub.a21,  <Formula 1> wherein, in Formula 1, A.sub.1 is a group represented by Formula 2, A.sub.2 is a group represented by Formula 3, and a21 is an integer of 1 to 11, wherein, when a21 is 2 to 11, two or more of A.sub.2 are identical to or different from each other:

##STR00001##

Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.

Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.

Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.

Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.

The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.

The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.